Drugs, Drugmaker | featured news

J&J AIDS drug shows promise

J&J AIDS drug shows promise

Two pivotal trials of a Johnson & Johnson experimental HIV drug found it worked as well as an existing drug, with fewer side effects but also with nearly twice as many patients failing to respond to treatment.

 

Pfizer to cut 6,000 jobs, close more plants

Drugmaker Pfizer will cut 6,000, or 18 percent, of jobs at its 78 manufacturing plants over the next five years as it consolidates operations after  last year's purchase of  Wyeth.

 

Johnson & Johnson buys 18 percent stake in Crucell

Health care giant Johnson & Johnson is jumping into the increasingly hot vaccine business by taking an 18 percent stake in Dutch biotechnology company Crucell NV and focusing more on preventive medicine....

 

Solvay sells drugs unit to Abbott for $6.6 billion

Belgian drugs, chemicals and plastics maker Solvay said on Monday it would sell its drugs unit to U.S. partner Abbott Laboratories for 4.5 billion euros ($6.61 billion) in cash and reinvest in chemicals and plastics.

 

J&J to Take Stake in Elan

J&J to Take Stake in Elan

J&J agreed to buy an 18.4% stake in Elan for $1 billion and acquire the rights to much of the Irish biotech company's research into drugs for Alzheimer's disease.

 

Merck to buy Schering-Plough in $41.1 billion deal

Merck to buy Schering-Plough in $41.1 billion deal

Drugmakers Merck & Co. and Schering-Plough Corp. are planning to merge under the name Merck in a stock-and-cash deal worth about $41.1 billion.

 

Subscribe to this RSS topic: Syndicate content